QIAGEN launches “Digital NGS” solutions with unique Molecular Index Technology to reliably detect all genetic variation
QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights
Hilden, Germany, and Germantown, Maryland, July 27, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary “Digital NGS” technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.
Coupled with advanced primer design and proprietary assay chemistry, the QIAseq Targeted panels enable reliable detection of extremely rare (low-frequency) mutations as well as highly efficient sequencing of GC-rich regions. In addition, this approach ensures accurate identification and quantitation of otherwise frequently undetected genetic variations. These features address important, previously only poorly addressed customer needs.
The QIAseq panels are incorporated into highly integrated Sample to Insight workflows, which include cloud-based bioinformatics for advanced data analysis and interpretation. They can be used for all common sample types and are available for various commercial NGS platforms. The assay roadmap for QIAGEN’s GeneReader NGS System also builds on Digital NGS, adding another, very unique advantage to this fully automated NGS workflow solution.
In addition to the launch of the predesigned DNA and RNA panels, QIAGEN also announced the availability of a customized panel design service to allow customers unlimited content breadth for Digital NGS panels because of novel chemistry and assay design. This service leverages QIAGEN’s strong position as a provider of pre-validated content that today already covers more than 60,000 gene targets.
“QIAseq targeted panels deliver reliable NGS results from even the most difficult tissue and liquid biopsy samples, enabling researchers to explore the deepest levels of genetic variation yielding invaluable molecular insights. QIAGEN is launching a full and comprehensive NGS portfolio leveraging this novel and proprietary approach,” said Brad Crutchfield, Senior Vice President of QIAGEN’s Life Sciences Business Area. “While NGS holds great potential, users face significant technical challenges. QIAGEN is helping customers solve these problems with innovative new solutions across the value chain, from sample technologies, enrichment and library preparation to actionable insights.”
As translational and clinical researchers increasingly embrace NGS analysis, problems can arise from limited, degraded and fragmented nucleic acids. These issues can lead to failure of experiments or confounding data from amplification errors biasing results. Digital NGS uses Unique Molecular Indices (UMIs) to tag every molecule in a sample at an early stage with a unique marker to eliminate these errors from downstream analysis. QIAseq targeted panels have been demonstrated to produce materially higher-quality data from sequencing, enabling detection of low-frequency variants in DNA, as well as gene expression analysis from RNA even from small samples.
The Digital NGS-based QIAseq Products QIAGEN is launching include:
- QIAseq Targeted DNA Panels – combining UMIs and unique chemistry to reliably detect low-frequency gene variants and access challenging genomic regions including GC-rich areas
- QIAseq Targeted RNAscan Panels – incorporating UMIs into sequencing of RNA-derived libraries for more sensitive, quantitative detection of known and novel gene fusions
- QIAseq miRNA NGS Kits – solving major issues in workflow and contamination of unwanted sequencing reads to deliver high-quality, Digital NGS with unbiased quantitation (third quarter 2016)
- QIAseq Targeted RNAseq Kits – utilizes UMIs for accurate gene expression quantitation of up to 1000 targets from as little as 10ng RNA input, including FFPE or fragmented RNA
More information on QIAGEN’s Digital NGS technology and the new QIAseq panels can be found www.qiagen.com/
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).